[New and emerging drugs for uric arthritis]

Gout is one of the most common forms of arthritis in the developed countries. Nevertheless, it is poorly managed mainly due to limited options in drug treatment, lack of widely accepted treatment strategies and underestimation of the importance of the disease. A significant proportion of especially elderly patients with gout are either unresponsive to or intolerant of the use of currently available medications. In the past decade we are witnessing the rise in gout prevalence and improvement in our understanding of its pathophysiology which both leaded to resurgence in scientist and clinician interest. Herewith are presented new medications for gout that act through different mechanism: anti-interleukin (IL)-1 drugs (anakinra, canakinumab, rilonacept) terminate the symptoms of acute gouty arthritis, febuxostat is a new selective xanthine oxidase inhibitor, poly(ethylene) glycol-uricase is a recently developed uricolytic as well as some new uricosuric agents. These innovatory drugs alongside with the concept of treat-to-target, with clear serum urate cut off, will help in the management of patients with gout.